title: Adipocytokines and squamous cell carcinoma of the esophagus.
abstract: OBJECTIVE
  Adipocytokines are adipocyte-secreted hormones associated with some malignancies. It has been reported that the impaired response of adipocytokines to body weight loss may play a role in the pathogenesis of cancer-induced cachexia. We investigated the association between adipocytokines with squamous cell carcinoma of the esophagus (SCCE).
  
  
  METHODS
  The levels of body mass index (BMI) and adiponectin, leptin, resistin, visfatin and C-peptide in the blood at diagnosis were measured in 117 SCCE patients and 117 age- and sex-matched controls. Logistic regression models were employed to estimate odds ratio. One-way analysis was performed to examine the prevalence of variables between two or more groups. A non-parametric Spearman correlation test was conducted to examine the associations between BMI and other variables.
  
  
  RESULTS
  Adiponectin and BMI levels were significantly lower, and resistin level was significantly higher in the patients on multivariate analysis (P = 0.01, <0.01 and <0.01 respectively). BMI gradually decreased with stage progression, and resistin level gradually increased with stage progression (P < 0.01 for both). The inverse correlation between BMI and adiponectin was comparatively strong in the controls, but was weak in the patients. Leptin showed comparatively strong correlation with BMI in the controls, but was weakly correlated in the patients. The correlation between BMI and resistin or C-peptide was demonstrated weakly only in the controls, and visfatin did not correlate with BMI.
  
  
  CONCLUSIONS
  Resistin may be a biomarker for the progression of SCCE. In addition, the impaired responses to body weight loss of adiponectin and leptin in the patients with SCCE were suggested.
authors.affiliation: Gastrointestinal Oncology Division, National Cancer Center Hospital, Tokyo, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
authors.forename: Takako Eguchi
authors.initials: TE
authors.lastname: Nakajima
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Yamada
authors.forename: Tetsutaro
authors.initials: T
authors.lastname: Hamano
authors.forename: Koh
authors.initials: K
authors.lastname: Furuta
authors.forename: Ichiro
authors.initials: I
authors.lastname: Oda
authors.forename: Hoichi
authors.initials: H
authors.lastname: Kato
authors.forename: Ken
authors.initials: K
authors.lastname: Kato
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hamaguchi
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Shimada
mesh_terms: D054392:Adipokines / Q000097:blood*; D052242:Adiponectin / Q000097:blood; D000368:Aged; D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000097:blood*; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood; D002100:Cachexia / Q000097:blood / Q000209:etiology; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000150:complications; D016022:Case-Control Studies; D018450:Disease Progression; D004938:Esophageal Neoplasms / Q000097:blood* / Q000150:complications; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood; D016017:Odds Ratio; D052243:Resistin / Q000097:blood
chemical_list: D054392:Adipokines; D052242:Adiponectin; D014408:Biomarkers, Tumor; D002096:C-Peptide; D020738:Leptin; D052243:Resistin; D054409:Nicotinamide Phosphoribosyltransferase
references.citation: J Biol Chem. 2005 May 6;280(18):18341-7
references.pmid: 15734737
references.citation: Eur J Cancer. 2008 Aug;44(12):1744-53
references.pmid: 18515085
references.citation: Int J Cancer. 2004 Mar;109(1):149-52
references.pmid: 14735482
references.citation: J Gastroenterol. 2009;44(7):685-90
references.pmid: 19430715
references.citation: Cancer. 2006 Feb 15;106(4):966-73
references.pmid: 16411208
references.citation: Circulation. 2004 May 4;109(17):2046-9
references.pmid: 15096450
references.citation: J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920
references.pmid: 15867843
references.citation: Cytokine. 2004 Jul 21-Aug 7;27(2-3):90-2
references.pmid: 15242698
references.citation: Int J Colorectal Dis. 2009 Mar;24(3):275-81
references.pmid: 18979105
references.citation: J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94
references.pmid: 16288122
references.citation: Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):466-72
references.pmid: 15701829
references.citation: Am J Gastroenterol. 2008 Jun;103(6):1358-64
references.pmid: 18510610
references.citation: Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
references.pmid: 10092513
references.citation: World J Gastroenterol. 2008 Jun 21;14(23):3633-41
references.pmid: 18595130
references.citation: Blood. 2000 Sep 1;96(5):1723-32
references.pmid: 10961870
references.citation: J Nutr. 2001 Nov;131(11 Suppl):3109S-20S
references.pmid: 11694656
references.citation: Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2697-703
references.pmid: 18086776
references.citation: Oncogene. 2004 Aug 23;23(38):6365-78
references.pmid: 15322511
references.citation: Cancer Causes Control. 2001 Jan;12(1):13-21
references.pmid: 11227921
references.citation: J Clin Endocrinol Metab. 2003 Apr;88(4):1748-52
references.pmid: 12679468
references.citation: Cancer Causes Control. 2009 Mar;20(2):193-9
references.pmid: 18814045
references.citation: Clin Endocrinol (Oxf). 2004 Sep;61(3):332-8
references.pmid: 15355449
references.citation: J Clin Endocrinol Metab. 2001 Aug;86(8):3815-9
references.pmid: 11502817